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Effect of Intraportal Human Islet Transplantation on Kidney Graft 
Survival in Simultaneous Kidney-Islet Allografts 
H.R. Rilo, P.B. Carroll, R. Shapiro, P. Fontes, V. Scantlebury, W. Irish, A.G. Tzakis, T.E. Starzl, 
and C. Ricordi 
AN increased frequency of acute kidney rejection 
episodes has been observed following simultaneous 
kidney and pancreas transplantation. 1-4 This has not been 
noted in all series.5•6 The mechanism of how the pancreas 
graft might induce rejection in the transplanted kidney is 
not known. We examined the frequency of kidney rejec-
tion episodes in patients who underwent combined kid-
ney-islet transplantation. 
METHODS 
Eight patients aged 29 to 38 years with long-standing insulin-
dependent (type 1) diabetes mellitus received nine combined 
cadaveric kidney-islet grafts (one retransplant), with one (n = 6). 
two (n = 2), or three (n = I) islet donors. The cadaveric donor 
ABO types were all compatible with recipient types and HLA 
matching was random, the antigen match being 0 to 2 for the 
kidney and 0 to 3 for islets. All patients had a negative cross-
match. One patient who underwent the procedure died on the fifth 
postoperative day of aspiration pneumonia. This was not included 
in the analysis of frequency of rejection, but data are included in 
the calculation of mortality and graft survival. 
Human islets were obtained as previously described.8 The islets 
were transplanted by infusion into a branch of the portal vein. 
All patients received a 1000-mg bolus of methylprednisolone 
during the operation, followed by a decreasing prednisone dose 
from 200 to 20 mg over the course of the first week posttransplant. 
FK 506 was given at a dose of 0.1 mWJ<g intravenously adminis-
tered as a continuous infusion over 24 hours, beginning immedi-
ately following transplantation. When patients resumed a solid 
diet, an oral dose of 0.15 mg/kg/BID was started. Patients 6 to 8 
also received imuran 200 mg/d during the first postoperative week 
in addition to the previously mentioned immunosuppression. 
Data were analyzed by XZ test with continuity correction. 
Significance of difference was considered as P :s; .05. 
RESULTS AND DISCUSSION 
Six-month graft survival was 86%, 76%. and 78% in 
diabetic recipients of a kidney graft (DK), nondiabetic 
kidney transplant recipients (NDK), and diabetic recipi· 
ents of kidney and islets (DKI), respectively. One-year 
graft survival was 82% (DK), 73% (NDK). and 78% (DKI). 
Mortality rates were not different in the groups. The 
unexpected finding was the frequency of kidney rejection 
episodes, 55.1% in DK, 65% in NDK, and 100% in DKI 
patients (P < .02). Most rejection episodes were mild and 
easily treated with corticosteroids. Only one graft was lost 
to refractory recurrent rejection episodes. After rejection 
episodes, five patients still have demonstrable islet cell 
function but all patients still require exogenous insulin. 
The best results were obtained in patients who received 
more than one donor. 
Although the number of patients in our kidney islet 
group is small. the frequency of rejection episodes seems 
out of proportion to what was expected for islet transplan-
tation. As with kidney and pancreas grafts. these rejection 
episodes are largely manageable. There were no significant 
differences in HLA matches in the three groups. 
The immunogenicity of the islet preparations or the 
intravascular route of administration (portal vein) could be 
determining factors in the increased frequency of kidney 
rejection observed. Despite the small volume and relative 
purity of the islet preparations. significant contaminating 
cells are still present. 7 These cells, which include lymphoid 
and dendritic cells, could be responsible for an increased 
immunogenicity of the islet graft. 
Our data also indicate that a single mild rejection epi-
sode. even in a patient who receives islets from multiple 
donors. may be enough to compromise the ability to 
achieve complete insulin independence, although diabetes 
control may be stabilized.8 
In conclusion, an increased frequency of kidney rejec· 
tion episodes was observed after combined kidney-islet 
allotransplantation. However. most of these rejection ep-
isodes were mild and did not produce any significant 
difference in patient and kidney graft survival. 
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